NCT03797053

Ex Vivo Expansion of Circulating Tumor Cells as a Model for Cancer Predictive Pharmacology

Expansion ex Vivo Des Cellules Tumorales Circulantes Comme modèle de Pharmacologie prédictive Des Cancers. EXPEVIVO-CTC

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 450 (estimated)
• Sponsor: Assistance Publique - Hôpitaux de Paris · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Several studies conducted over the past decade have shown that Circulating tumor cells (CTCs) can be used as a marker for predicting disease progression and survival in patients with early or metastatic cancer. A high number of CTCs correlate with aggressive disease, increased metastasis and decreased survival rates. Knowledge of metastasis mechanisms was mainly obtained from mouse models with CTCs after orthotopic transplants. The only possibility to study the patient's CTC subpopulations is to carry out ex-vivo expansion and develop an animal model with CTC xenograft. Because circulating blood collection is simple and non-invasive, CTCs can be used as a marker to track disease progression and survival in real time. CTCs could also guide therapeutic choice.

Conditions

• Melanoma
• Circulating Tumor Cell

Interventions

Type	Name	Description
PROCEDURE	Biological sample	Biological sample performed : * before treatment * 1 months after the beginning of treatment * every tumoral assessment

Timeline

• Start date: 2015-04-06
• Primary completion: 2019-06-30
• Completion: 2019-06-30
• First posted: 2019-01-08
• Last updated: 2019-01-08

Locations

1 site across 1 country: France